Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yoshimasa Inoue

Showing results (41-50 of 91) with videos related to

Pageof 10
Sort By:
Therapeutic Drug Monitoring|March 24, 2018
Effects of Cytochrome P450 (CYP) 2C19 Genotypes on Steady-State Plasma Concentrations of Escitalopram and its Desmethyl Metabolite in Japanese Patients With DepressionShoko Tsuchimine, Shinichiro Ochi, Misuzu Tajiri, et al.
Therapeutic Drug Monitoring|June 17, 2006
Effects of caffeine on the kinetics of fluvoxamine and its major metabolite in plasma after a single oral dose of the drugTakashi Fukasawa, Norio Yasui-Furukori, Akihito Suzuki, et al.
British Journal of Clinical Pharmacology|March 18, 2004
Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypesNorio Yasui-Furukori, Takenori Takahata, Taku Nakagami, et al.
Therapeutic Drug Monitoring|July 17, 2004
Steady-state pharmacokinetics of a new antipsychotic agent perospirone and its active metabolite, and its relationship with prolactin responseNorio Yasui-Furukori, Hanako Furukori, Taku Nakagami, et al.
Human Psychopharmacology|April 8, 2010
Prolactin fluctuation over the course of a day during treatments with three atypical antipsychotics in schizophrenic patientsNorio Yasui-Furukori, Hanako Furukori, Norio Sugawara, et al.
Human Psychopharmacology|November 22, 2011
Inverse correlation between clinical response to paroxetine and plasma drug concentration in patients with major depressive disordersNorio Yasui-Furukori, Taku Nakagami, Ayako Kaneda, et al.
Therapeutic Drug Monitoring|May 29, 2004
Establishment of new cloned enzyme donor immunoassays (CEDIA) for haloperidol and bromperidolNorio Yasui-Furukori, Manabu Saito, Hanako Furukori, et al.
European Journal of Clinical Pharmacology|November 25, 2006
Terbinafine increases the plasma concentration of paroxetine after a single oral administration of paroxetine in healthy subjectsNorio Yasui-Furukori, Manabu Saito, Yoshimasa Inoue, et al.
Journal of Psychopharmacology (Oxford, England)|June 16, 2010
CYP2D6 genotype and smoking influence fluvoxamine steady-state concentration in Japanese psychiatric patients: lessons for genotype-phenotype association study design in translational pharmacogeneticsYutaro Suzuki, Takuro Sugai, Naoki Fukui, et al.
Journal of Clinical Pharmacology|October 5, 2002
Lack of correlation between the steady-state plasma concentrations of haloperidol and risperidoneNorio Yasui-Furukori, Tsuyoshi Kondo, Kazuo Mihara, et al.
Pageof 10

Showing results (41-50 of 91) with videos related to

Sort By:
Pageof 10
Therapeutic Drug Monitoring|March 24, 2018
Effects of Cytochrome P450 (CYP) 2C19 Genotypes on Steady-State Plasma Concentrations of Escitalopram and its Desmethyl Metabolite in Japanese Patients With DepressionShoko Tsuchimine, Shinichiro Ochi, Misuzu Tajiri, et al.
Therapeutic Drug Monitoring|June 17, 2006
Effects of caffeine on the kinetics of fluvoxamine and its major metabolite in plasma after a single oral dose of the drugTakashi Fukasawa, Norio Yasui-Furukori, Akihito Suzuki, et al.
British Journal of Clinical Pharmacology|March 18, 2004
Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypesNorio Yasui-Furukori, Takenori Takahata, Taku Nakagami, et al.
Therapeutic Drug Monitoring|July 17, 2004
Steady-state pharmacokinetics of a new antipsychotic agent perospirone and its active metabolite, and its relationship with prolactin responseNorio Yasui-Furukori, Hanako Furukori, Taku Nakagami, et al.
Human Psychopharmacology|April 8, 2010
Prolactin fluctuation over the course of a day during treatments with three atypical antipsychotics in schizophrenic patientsNorio Yasui-Furukori, Hanako Furukori, Norio Sugawara, et al.
Human Psychopharmacology|November 22, 2011
Inverse correlation between clinical response to paroxetine and plasma drug concentration in patients with major depressive disordersNorio Yasui-Furukori, Taku Nakagami, Ayako Kaneda, et al.
Therapeutic Drug Monitoring|May 29, 2004
Establishment of new cloned enzyme donor immunoassays (CEDIA) for haloperidol and bromperidolNorio Yasui-Furukori, Manabu Saito, Hanako Furukori, et al.
European Journal of Clinical Pharmacology|November 25, 2006
Terbinafine increases the plasma concentration of paroxetine after a single oral administration of paroxetine in healthy subjectsNorio Yasui-Furukori, Manabu Saito, Yoshimasa Inoue, et al.
Journal of Psychopharmacology (Oxford, England)|June 16, 2010
CYP2D6 genotype and smoking influence fluvoxamine steady-state concentration in Japanese psychiatric patients: lessons for genotype-phenotype association study design in translational pharmacogeneticsYutaro Suzuki, Takuro Sugai, Naoki Fukui, et al.
Journal of Clinical Pharmacology|October 5, 2002
Lack of correlation between the steady-state plasma concentrations of haloperidol and risperidoneNorio Yasui-Furukori, Tsuyoshi Kondo, Kazuo Mihara, et al.
Pageof 10